Clostridium difficile infection

临床试验

计划入组 15 人 · 首次发布于 2021 年 5 月 6 日

已完成

NCT03107169

Treatment of Initial Clostridium Difficile Infection

计划入组 10 人 · 首次发布于 2017 年 4 月 11 日

终止

NCT02301000

IMT for Primary Clostridium Difficile Infection

计划入组 21 人 · 首次发布于 2014 年 11 月 25 日

药物

查看全部 607 →

Therapeutic vaccine (Clostridium difficile infection)

conjugate vaccine (MAPS, Clostridium difficile infection)

Small Molecule

Approved

Fidaxomicin(Dificid, Dificlir)

相关疾病：Clostridium Difficile Associated Diarrhea (CDAD)

C₅₂H₇₄Cl₂O₁₈ · Rx

机构

查看全部 27 →

FIRST MEDICAL INFECTION CONTROL ASSOCIATES, INC.

United States

B. Braun Ltd. Centre of Excellence Infection Control

Theriva Biologics

United States

资讯

查看全部 3031 →

去年

FDA Advisory Committee Supports Merck's Bezlotoxumab for Clostridium difficile Infection Recurrence Prevention

去年

Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis

去年

临床试验

Monoclonal Antibodies in Clostridium Difficile Infection

Treatment of Initial Clostridium Difficile Infection

IMT for Primary Clostridium Difficile Infection

药物

Therapeutic vaccine (Clostridium difficile infection)

conjugate vaccine (MAPS, Clostridium difficile infection)

Fidaxomicin(Dificid, Dificlir)

机构

FIRST MEDICAL INFECTION CONTROL ASSOCIATES, INC.

B. Braun Ltd. Centre of Excellence Infection Control

Theriva Biologics

资讯

FDA Advisory Committee Supports Merck's Bezlotoxumab for Clostridium difficile Infection Recurrence Prevention

Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis

Fecal Microbiota Transplantation Shows Promise in Amyotrophic Lateral Sclerosis